European Society for Medical Oncology Congress

The latest news from ESMO, including researcher interviews and physician perspective.


Meeting News Coverage

Nivolumab effective in pretreated metastatic or surgically unresectable urothelial cancer

October 9, 2016
COPENHAGEN, Denmark — Second-line nivolumab monotherapy demonstrated clinically meaningful efficacy in patients with metastatic or surgically…
Meeting News Coverage

Atezolizumab prolongs OS in previously treated NSCLC

October 9, 2016
COPENHAGEN, Denmark — Atezolizumab significantly extended OS compared with docetaxel in patients receiving second-line or third-line treatment…
Meeting News Coverage

Pembrolizumab extends survival in advanced, PD-L1–positive NSCLC

October 9, 2016
COPENHAGEN, Denmark — Pembrolizumab significantly extended PFS and OS compared with platinum-based chemotherapy among untreated patients with…
Meeting News Coverage

First-line pembrolizumab plus chemotherapy improves response rates, PFS in advanced NSCLC

October 9, 2016
COPENHAGEN, Denmark — The addition of pembrolizumab to standard first-line chemotherapy with carboplatin and pemetrexed significantly improved…
Meeting News Coverage

Ceritinib extends PFS in pretreated patients with ALK–rearranged NSCLC

October 9, 2016
COPENHAGEN, Denmark — Ceritinib significantly prolonged PFS compared with chemotherapy in patients with anaplastic lymphoma…
Meeting News Coverage

Dabrafenib, trametinib improve 3-year OS in advanced BRAF–mutated melanoma

October 9, 2016
COPENHAGEN, Denmark — Dabrafenib plus trametinib demonstrated long-term safety and efficacy in patients with unresectable, metastatic BRAF
Meeting News CoveragePerspective

Neoadjuvant chemoradiotherapy improves survival in locally advanced esophageal squamous cell carcinoma

October 9, 2016
COPENHAGEN, Denmark — The addition of neoadjuvant chemoradiotherapy to surgery extended OS in patients with locally advanced esophageal…
Meeting News Coverage

Fulvestrant extends PFS in certain postmenopausal women with breast cancer

October 8, 2016
COPENHAGEN, Denmark — Fulvestrant significantly prolonged PFS compared with anastrozole among women with hormone receptor–positive…
Meeting News CoveragePerspective

Olaparib fails to extend OS in advanced gastric cancer

October 8, 2016
COPENHAGEN, Denmark — The addition of olaparib to paclitaxel demonstrated a trend toward an OS benefit in patients with advanced gastric cancer…
Meeting News Coverage

Niraparib prolongs PFS in recurrent ovarian cancer

October 8, 2016
COPENHAGEN, Denmark — Niraparib maintenance therapy significantly extended PFS compared with placebo in women with platinum-sensitive recurrent…